Stephen Oh, MD
Hematology · Saint Louis, MONPI 1841494358
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $106,218 of the $142,710 with a category attached, or 74.4%. 16 manufacturers reported payments, led by Incyte Corporation at 49.0% of the total. Among hematology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $1065.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$70K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- Blueprint Medicines Corporation$10K
- CTI Biopharma Corp.$9K
- AbbVie$8K
- Pharmaessentia USA Corporation$7K
- plus $24K from 10 others
Across 1,065 payments — averaging $3118.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.6M
- Pharmaessentia USA Corporation$555K
- Blueprint Medicines Corporation$493K
- Novartis$318K
- Bristol Myers Squibb$167K
- Takeda Pharmaceuticals U.S.A., Inc.$71K
- plus $113K from 5 others
What the payments were for
- Consulting fees$106,21874%
- Speaking & faculty fees$28,58420%
- Travel & lodging$5,2634%
- Food & beverage$2,6382%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 60 | $69,883 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $15,711 |
| Blueprint Medicines Corporation | 5 | $9,518 |
| CTI Biopharma Corp. | 15 | $9,187 |
| AbbVie | 9 | $7,948 |
| Pharmaessentia USA Corporation | 3 | $6,888 |
| Bristol Myers Squibb | 7 | $5,846 |
| GSK | 13 | $5,534 |
| E.r. Squibb & Sons, L.L.C. | 3 | $5,044 |
| Merck | 1 | $4,270 |
| Morphosys, US Inc. | 1 | $2,600 |
| Eli Lilly | 1 | $148 |
| Sobi, Inc | 3 | $74 |
| Novo Nordisk | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| HEMA Biologics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,710 in reported general payments places this provider in the 95th percentile of 27 hematology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 236 | $4,065,383 |
| AyvakitAvapritinib | 24 | $905,855 |
| OjjaaraMomelotinib Dihydrochloride | 28 | $791,220 |
| BesremiRopeginterferon Alfa-2b-Njft | 17 | $295,105 |
| TasignaNilotinib Hcl | 14 | $273,932 |
| Hydroxyurea | 124 | $3,735 |
| Anagrelide Hcl | 26 | $2,869 |
| Allopurinol | 11 | $150 |
| Ondansetron OdtOndansetron | 14 | $5 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $69,883 | $4,065,383236 claims |
| Blueprint Medicines CorporationAyvakit | $9,518 | $905,85524 claims |
| GSKOjjaara | $5,534 | $791,22028 claims |
| Pharmaessentia USA CorporationBesremi | $6,888 | $295,10517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 27 hematology providers in Missouri.
Other hematology in Saint Louis
- Morey BlinderSaint Louis$235K
- Elaine MajerusSaint Louis$111K
- Govind BhagatSaint Louis$67K
- Amy ZhouSaint Louis$18K
- Shaun HansonSaint Louis$15K
- Stuart KornfeldSaint Louis$4K
- Joshua SinerSaint Louis$1K
- Andrew YoungSaint Louis$789
- Kristen SanfilippoSaint Louis$354
- Amber AfzalSaint Louis$127
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.